Fortis Healthcare Limited has completed the mandatory newspaper publication of its Q3 FY26 unaudited financial results under SEBI regulations, following the company's strong financial performance for the quarter ended December 31, 2025. The healthcare giant reported consolidated revenues of INR 2,265 Cr, marking a significant 17.5% increase compared to Q3 FY25. Subsequently, the company held its earnings conference call on February 16, 2026, providing detailed insights into operational performance and future expansion plans.

Regulatory Compliance and Publication Details

Pursuant to Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published its financial results on February 14, 2026, in English daily "Financial Express" (all editions) and Punjabi daily "Rozana Spokesman" (Mohali edition). The publication ensures transparency and accessibility of financial information to all stakeholders. Additionally, the company released the transcript of its investors/analysts meet held on February 16, 2026, under Regulation 30.

Strong Financial Performance Highlights

The consolidated financial results showcase robust operational efficiency across both hospital and diagnostics businesses, with significant margin expansion and revenue growth. During the earnings call, MD and CEO Dr. Ashutosh Raghuvanshi highlighted the sustained growth momentum despite seasonal impacts from festivals in key geographies.

For the nine-month period ended December 31, 2025, consolidated revenues reached INR 6,763 Cr, demonstrating consistent growth momentum with a 17.1% increase. The company's net debt stands at INR 2,547 Cr with a net debt to EBITDA ratio of 1.24x as of December 31, 2025.

Hospital Business Drives Growth

The hospital business segment emerged as the primary growth driver, with revenues increasing substantially and margins improving across key specialties. Management noted that 13 facilities reported operating EBITDA above 20% during the nine-month period, contributing 77% of hospital revenues.

Strategic Acquisitions and Expansion Plans

During the earnings call, management announced the acquisition of 125-bedded People Tree Hospital in Yeshwanthpur, Bengaluru for INR 430 Cr in January 2026. The acquisition includes underlying land and an adjacent land parcel enabling future expansion to over 300 beds. The company also launched Adayu, a 36-bedded specialized mental health care facility in Gurugram in November 2025.

Diagnostics Business Performance

Agilus Diagnostics reported gross revenues of INR 371 Cr, reflecting 8.3% year-on-year growth. Operating EBITDA margin improved significantly to 23.1% from 14.4% in Q3 FY25. The business conducted 9.9 million tests during the quarter with a balanced B2C-B2B mix of 52-48.

Management Outlook and Future Strategy

CFO Vivek Goyal indicated expectations of continued growth trajectory with 4-5% ARPOB increases going forward. The company expects potential equity infusion from parent IHH Healthcare post the cooling period ending in May 2026. Management expressed confidence in maintaining growth momentum through brownfield expansions, strategic acquisitions, and operational improvements across existing facilities.

Fortis Healthcare Limited has provided an update on the ongoing material litigation involving its promoter shareholder Northern TK Venture Pte Ltd (NTK) against Daiichi Sankyo Company Limited before the Tokyo District Court in Japan. The healthcare company disclosed this development under Regulation 30 of SEBI Listing Regulations on February 19, 2026.

Latest Court Filing Development

On February 12, 2026, NTK submitted a petition to the Tokyo District Court to further amend its claim against Daiichi Sankyo. The court delivered the copy of this Petition to Amend Claims to Daiichi Sankyo on February 17, 2026. This filing represents the latest development in the ongoing legal proceedings that have been tracked through multiple announcements since November 2023.

Financial Claims and Relief Sought

NTK continues to seek substantial financial compensation and other reliefs from Daiichi Sankyo under applicable substantive laws:

The tortious claim amount is equivalent to RM5,708,268,325.95 and JPY199,785,395,700.48, while the defamation claim of JPY5,000,000 equals RM142,860.00 and INR2,735,419.14, based on exchange rates as of December 31, 2024.

Amended Injunctive Relief

The primary change in the amended petition relates to the injunctive claim against Daiichi Sankyo. Following the completion of open offers on November 10, 2025, NTK has modified its request for injunctive relief. The amended petition seeks to prevent Daiichi Sankyo from:

• Obstructing the acquisition of shares in Fortis and Malar by NTK
• Interfering with any other investment and corporate exercises related to Fortis and Malar
• Making defamatory statements to SEBI and other third parties, including the public

Background Transaction Details

The litigation stems from a complex transaction involving IHH Healthcare's subsidiary NTK and Fortis Healthcare. The original transaction included:

Additional Relief Sought

Beyond financial compensation and injunctive relief, NTK also seeks:

• Publication of a statement on Daiichi Sankyo's website to vindicate NTK's reputation
• Issuance of a statement to SEBI for reputation vindication purposes

NTK has reserved its rights to further amend the amount of damages in the current petition, indicating potential future modifications to the financial claims.

Corporate Disclosure

Fortis Healthcare's disclosure was made through its Company Secretary & Compliance Officer Satyendra Chauhan, referencing multiple previous announcements dating back to November 2023. The company has committed to informing stakeholders of any material developments in this litigation matter. IHH Healthcare, as the parent company of NTK, simultaneously announced this development to the Bursa Malaysia and Singapore Stock Exchanges, ensuring comprehensive market disclosure across relevant jurisdictions.